AXXO® Woundgel (also marketed as SmartGEL®) is a non-allergenic hydrogel based on Magle Group’s proprietary polymer technology, DSM® (Degradable Starch Microsphere). The product contains antimicrobials incorporated into fully biodegradable starch microspheres, which are suspended in a gel matrix for optimal infection prevention and treatment. The gel delivers moisture to the wound, whilst maintaining enough absorption capacity for exudate, debris and bacteria.

"The regulatory approval of AXXO® Woundgel in Kuwait is an important step in establishing the product in the Middle East. We are also looking forward to potential market approvals in Latin America, where applications have been submitted to regulatory authorities in Uruguay and Paraguay. Today’s announcement represents yet another example of our ability to continuously expand the geographical footprint of our proprietary DSM products," said Justin Pierce, CEO of Magle Group.

Magle Group is striving to continuously increase its revenues from existing DSM® products, both through intensified and geographically broadened direct sales activities and in alliances for marketing and distribution. In parallel, the company is pursuing the development of additional DSM® products through carefully balanced investments, with new market launches projected in the coming years.